Federal Circuit Vacates and Remands Incontinence Patent Ruling in Paul Hartmann AG v. Attends Healthcare
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Paul Hartmann AG v. Attends Healthcare Products, Inc. |
| Case Number | 22-1724 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from District of Columbia |
| Duration | Apr 2022 – Mar 2024 1 year 11 months |
| Outcome | Vacated & Remanded |
| Patents at Issue | |
| Accused Products | Attends Healthcare Products Incontinence Articles |
Case Overview
The Parties
⚖️ Plaintiff
German multinational corporation and leading manufacturer of medical and hygiene products, including disposable incontinence articles marketed globally.
🛡️ Defendant
U.S.-based manufacturer and distributor of incontinence care products, operating in direct commercial competition with Hartmann across multiple product categories.
The Patents at Issue
This dispute centered on four U.S. patents protecting an absorbent incontinence article with an improved closure system—a product category representing billions in annual global revenue and fierce competitive pressure. These utility patents cover innovations in absorbent incontinence article design, with a specific focus on improved closure systems.
- • U.S. Patent No. 8,708,990 — Absorbent incontinence article with closure system
- • U.S. Patent No. 8,152,788 — Improved fastening for absorbent articles
- • U.S. Patent No. 8,771,249 — Absorbent article with defined closure tabs
- • U.S. Patent No. 8,784,398 — System for securing absorbent hygiene products
Developing a similar medical product?
Check if your incontinence product design might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a Vacated and Remanded decision, returning the case for reconsideration. No damages were awarded at this stage, and no injunctive relief was confirmed as part of this appellate ruling. A “vacated and remanded” outcome indicates that the appellate court found legal error in the lower tribunal’s reasoning or application of law, warranting a revisit of the decision below.
Key Legal Issues
The controlling legal issue was patentability — specifically framed as an invalidity or cancellation action. This strongly suggests Attends challenged the asserted patents on grounds such as anticipation, obviousness under 35 U.S.C. § 103, or lack of written description or enablement under 35 U.S.C. § 112. The Federal Circuit’s decision to vacate and remand often signals disagreement with the lower tribunal’s claim construction, its application of the obviousness framework, or its evaluation of secondary considerations.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in absorbent article design. Choose your next step:
📋 Understand This Case’s Validity Issues
Learn about the specific risks and implications from this patentability litigation.
- View all 4 patents involved in the dispute
- Analyze prior art and obviousness arguments
- Understand claim scope and construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
Validity Uncertainty
Case remanded for further patentability review
4 Utility Patents
In incontinence article closure systems
Claim Construction Focus
Errors in prior ruling cited by CAFC
✅ Key Takeaways
Federal Circuit’s willingness to vacate signals rigorous appellate scrutiny of invalidity determinations, especially where claim construction errors may exist.
Search related case law →Multi-patent invalidity campaigns require careful coordination to avoid inconsistent positions and bolster arguments across related claims.
Explore precedents →Frequently Asked Questions
Four U.S. patents were at issue: U.S. 8,708,990; 8,152,788; 8,771,249; and 8,784,398, all covering absorbent incontinence article closure system technology.
The verdict cause was patentability, specifically an invalidity/cancellation action. The Federal Circuit found sufficient legal error in the lower ruling to vacate and return the case for further proceedings, without disclosing a final validity determination.
The remand preserves validity uncertainty, complicating FTO analysis and licensing negotiations for competitors in the incontinence product market until the lower tribunal issues a revised ruling.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- CourtListener — Paul Hartmann AG v. Attends Healthcare Products, Inc. (Case 22-1724)
- United States Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office — U.S. Patent No. 8,708,990
- Cornell Legal Information Institute — 35 U.S.C. § 103 (Obviousness)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.